- Revenue: $9.1B, +11% YoY
- Net income: $627M, -18% YoY
- Non-GAAP EPS: $5.31, +13% YoY
- Full year revenue: $33.4B, +19% YoY
CEO Robert A. Bradway: "Robust growth in sales and earnings throughout 2024 reflects the momentum of our business. With strong performance globally, we are investing heavily in our rapidly advancing pipeline to deliver innovative therapies across our four therapeutic areas."
🌱Revenue & Growth
- Product sales grew 11%, driven by 14% volume growth
- Ten products delivered double-digit sales growth in Q4
- Repatha sales: $606M, +45% YoY
- TEZSPIRE sales: $296M, +67% YoY
- Rare disease products: $1.2B in Q4
💰Profits & Financials
- Operating margin: 26.5% vs 16.2% in Q4 2023
- Free cash flow: $4.4B vs $0.3B in Q4 2023
- Cash and investments: $12.0B
- Total debt: $60.1B
- Debt leverage ratio: 4.5x EBITDA
📌Business Highlights
- Generated record $10.4B free cash flow for full year 2024
- Q4 dividend increased 6% YoY to $2.25 per share
- Repurchased 0.7M shares for $200M in Q4
🔮Future Outlook
- FY2025 revenue guidance: $34.3B-$35.7B
- Non-GAAP EPS guidance: $20.00-$21.20
- Capital expenditures expected around $2.3B
- Share repurchases not to exceed $500M